ALKERMES
Alkermes, Inc. is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. Alkermes, Inc. develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central... nervous system (CNS), disorders, reward disorders, addiction, diabetes and autoimmune disorders. The Company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. RISPERDAL CONSTA is used for the treatment of schizophrenia and for the treatment of bipolar I disorder. VIVITROL is an extended-release MEDISORB formulation of naltrexone, as a once-monthly injectable medication for the treatment of alcohol dependence.
ALKERMES
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1987-01-01
Address:
Dublin, Dublin, Ireland
Country:
Ireland
Website Url:
http://www.alkermes.com
Total Employee:
1001+
Status:
Active
Contact:
+353 1 772 8000
Email Addresses:
[email protected]
Total Funding:
250 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Apache Mobile Non Scaleable Content
Similar Organizations
Noema Pharma
Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system.
Xellera Therapeutics
Xellera Therapeutics is a biotechnology company discovers and develops therapeutic and regenerative medicine for the treatment of diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-11-18 | Rodin Therapeutics | Rodin Therapeutics acquired by Alkermes | N/A |
| 1999-07-13 | Advanced Inhalation Research | Advanced Inhalation Research acquired by Alkermes | N/A |
| 1993-01-01 | Enzytech | Enzytech acquired by Alkermes | N/A |
Investors List
Primecap Management
Primecap Management investment in Post-IPO Equity - Alkermes
Invesco
Invesco investment in Post-IPO Equity - Alkermes
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-08-25 | Civitas Therapeutics | Alkermes investment in Series C - Civitas Therapeutics | 55 M USD |
| 2013-09-11 | Civitas Therapeutics | Alkermes investment in Series B - Civitas Therapeutics | 38 M USD |
Newest Events participated
Participated in The Next Era in Innovation
on 2017-04-13 as sponsor
Official Site Inspections
http://www.alkermes.com Semrush global rank: 1.53 M Semrush visits lastest month: 17.23 K
- Host name: 72.32.33.202
- IP address: 72.32.33.202
- Location: San Antonio United States
- Latitude: 29.4963
- Longitude: -98.4004
- Metro Code: 641
- Timezone: America/Chicago
- Postal: 78218
